Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children

Inclusion Criteria

• •Subject aged between 0 - 17 years 10 months.
• •Subject admitted to a participating ward unit (Neonatal Intensive Care Unit, Pediatric Intensive Care Unit, Pediatric Hematology-Oncology unit).
• •Strongly suspected or confirmed systemic infection.
• •Subject planned to start on intravenous amoxicillin-clavulanic acid, piperacillin-tazobactam or meropenem treatment at least aimed for a minimum duration of two days at time of inclusion. If the subject was previously treated with the same beta-lactam, the minimum interval to the previous beta-lactam treatment episode is
• •40 hours for amoxicillin-clavulanic acid (based on elimination half-life)
• •8 hours for piperacillin-tazobactam and meropenem (based on elimination half-life) Subject planned to start on intravenous amoxicillin (without clavulanic acid) will not be included.
• •Informed consent/assent signed by parents or legal representatives of the subject.
• •Not previously enrolled in this trial.